Evoke Pharma Dividends and Buybacks
Dividend criteria checks 0/6
Evoke Pharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-107.5%
Buyback Yield
| Total Shareholder Yield | -107.5% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22
Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if EVOK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVOK's dividend payments have been increasing.
Dividend Yield vs Market
| Evoke Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (EVOK) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Pharmaceuticals) | 2.6% |
| Analyst forecast (EVOK) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate EVOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate EVOK's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EVOK has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 18:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evoke Pharma, Inc. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Edward Woo | Ascendiant Capital Markets LLC |
| Difei Yang | Brean Capital |